ACM derived from OGJ patients with early-stage tumours significantly increased the frequency of naïve CD4+ T cells compared with untreated cells (untrx: 34.53 ± 2.9 vs. early-stage: 43.39 ± 3.1%, p = 0.03) (Fig. 1B). The gene discussed is CD4; the disease is neoplasm.